Meeting the human
Journal Title: OncoReview - Year 2013, Vol 3, Issue 1
Abstract
We often have to deal with problems which force us to making difficult choices and decisions that have not only clinical aspects but also ethical during the oncologist’s work. Unfortunately there is not enough place in available medical literature given for dilemmas which oncologists meet in their work. We would like to encourage you to share your doubts and present descriptions of situations which were difficult for you in the pages of our newspaper. By example of a patient who got treatment in our hospital we present dilemmas which appeared in our mutual contacts and became an inspiration to further thoughts. We also discuss such issues as doctor’s attitude to dying patient, the problem of restricting medical procedures and patient–doctor relation.
Authors and Affiliations
Anna Walaszkowska-Czyż, Małgorzata Kuc-Rajca
Keywords
Related Articles
- EP ID EP53194
- DOI -
- Views 233
- Downloads 0
Nowe dane dotyczące leczenia pacjentów z nowotworami układu moczowo-płciowego prezentowane w trakcie corocznego zjazdu American Society of Clinical Oncology w 2011 r.
WSTĘP: W dniach 3.06.2011–06.06.2011 r. w Chicago (USA) odbył się coroczny zjazd ASCO (American Society of Clinical Oncology).MATERIAŁ I METODY: Materiał omówiono z podziałem na zagadnienia dotyczące nowotworów zarodkowy...
Mindfulness in the treatment of chronic pain and improvement in the quality of life of both oncological and non-oncological patients
Pain, which accompanies almost every third Pole, is an ever greater medical, psychological and social challenge. Relieving pain, and chronic one in particular, is now becoming one of the most important tasks for contempo...
Exemestan in breast cancer treatment
Hormonotherapy is one of the most important therapeutic options in the breast cancer treatment, either locally advanced or metastatic. Tamoxifen has been standard of care for many years, however new clinical trials resul...
Early molecular response as a criterion of optimal response to chronic myeloid leukemia treatment with tyrosine kinase inhibitors
Maximal reduction of leukemic BCR/ABL-positive cells and achievement of persistent deep molecular response with the chance for sustained treatment-free survival in possibly all patients is a current goal of chronic myelo...
Adjuvant imatinib after resection of gastrointestinal stromal tumour – systematic review and meta-analysis
[b]Background[/b]: Adjuvant therapy is recommended for the population of patients with high risk of recurrence of gastrointestinal stromal tumour after resection.[b]The aim of the study[/b]: Evaluation of the clinical ef...